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Randomized phase 1b trial of MOR103,
a human antibody to GM-CSF, in
multiple sclerosis
ABSTRACT
Objectives: To determine the safety, pharmacokinetics (PK), and immunogenicity of the recombi-
nant human monoclonal antibody MOR103 to granulocyte-macrophage colony-stimulating factor
(GM-CSF) in patients with multiple sclerosis (MS) with clinical or MRI activity.
Methods: In this 20-week, randomized, double-blind, placebo-controlled phase 1b dose-escalation
trial (registration number NCT01517282), adults with relapsing-remitting MS (RRMS) or secondary
progressive MS (SPMS) received an IV infusion of placebo (n 5 6) or MOR103 0.5 (n 5 8), 1.0
(n 5 8), or 2.0 (n 5 9) mg/kg every 2 weeks for 10 weeks. Patients had to have #10
gadolinium (Gd)-enhancing brain lesions on T1-weighted MRI at baseline. The primary objective
was safety.
Results:Most treatment-emergent adverse events (TEAEs) were mild to moderate in severity. The
most frequent was nasopharyngitis. Between-group differences in TEAE numbers were small.
There were no TEAE-related trial discontinuations, infusion-related reactions, or deaths. Nine pa-
tients experienced MS exacerbations: 3, 5, 1, and 0 patient(s) in the placebo, 0.5, 1.0, and 2.0
mg/kg groups, respectively. A few T1 Gd-enhancing lesions and/or new or enlarging T2 lesions
indicative of inflammation were observed in all treatment groups. No clinically significant changes
were observed in other clinical assessments or laboratory safety assessments. No anti-MOR103
antibodies were detected. PK evaluations indicated dose linearity with low/no drug accumulation
over time.
Conclusions:MOR103was generally well-tolerated in patients with RRMS or SPMS. No evidence
of immunogenicity was found.
Classification of evidence: This phase 1b study provides Class I evidence that MOR103 has
acceptable tolerability in patients with MS. Neurol Neuroimmunol Neuroinflamm 2015;2:e117; doi:
10.1212/NXI.0000000000000117
GLOSSARY
AE 5 adverse event; AUCtau 5 area under the serum concentration vs time curve; DLCO 5 diffusing capacity of the lung for
carbon monoxide; DMC 5 data monitoring committee; EAE 5 experimental autoimmune encephalomyelitis; EDSS 5
Expanded Disability Status Scale; Gd 5 gadolinium; GM-CSF 5 granulocyte-macrophage colony-stimulating factor; IFN 5
interferon; IVIg 5 IV gamma globulin; IL 5 interleukin; MS 5 multiple sclerosis; PFT 5 pulmonary function test; PK 5 phar-
macokinetics; RRMS 5 relapsing-remitting MS; SPMS 5 secondary progressive MS; SSP-D 5 serum surfactant protein D;
TEAE 5 treatment-emergent AE.
Therapy for multiple sclerosis (MS) is a rapidly advancing area in neurologic research. Although
immunomodulatory agents are effective in reducing the frequency of exacerbations (relapses), a
considerable proportion of patients achieves only a suboptimal response to medication1; thus,
there remains an unmet need for effective and well-tolerated MS therapies, particularly for
patients with progressive disease.
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CNS infiltrating monocytes/macrophages
and resident microglia contribute to neuroin-
flammation and neurodegeneration in MS
through inflammatory mediator release and
stimulation of leukocyte activity.2 Granulocyte-
macrophage colony-stimulating factor (GM-
CSF) is a cytokine affecting functional activities
of mature myeloid cells. Among these, GM-
CSF promotes macrophage polarization and
subsequent inflammatory mediator produc-
tion.3,4 The frequency of GM-CSF–producing
cells is higher in patients with MS than in
patients with noninflammatory neurologic
diseases.5
In experimental autoimmune encephalo-
myelitis (EAE), a widely used MS model,6
GM-CSF is required for disease induction
and maintenance.7–9 GM-CSF 2/2 mice are
resistant to EAE, and anti-GM-CSF antibody
treatment in wild-type mice prevented the
onset of clinical disease but also ameliorated
disease score when administered therapeuti-
cally.7 It was observed that GM-CSF produced
by autoreactive T cells serves a nonredundant
function in the effector phase of EAE.10,11 In
addition, GM-CSF is required for recruitment
of peripheral myeloid cells into the CNS.9,10
Consequently, neutralizing antibodies against
GM-CSF might provide a new therapeutic
approach for MS.
MOR103 is a high-affinity recombinant
human immunoglobulin (Ig) G1 antibody,
blocking GM-CSF interaction with its recep-
tor and thereby preventing subsequent signal
transduction.12 MOR103 is a human IgG1
and, as with other IgGs, was therefore
expected to cross the blood-brain barrier at
low levels only. However, the blood-brain bar-
rier becomes broken down in MS lesions,13
potentially leading to increased IgG penetra-
tion. Based on EAE data, there is evidence of
GM-CSF having both a central role (e.g.,
GM-CSF production of CNS-infiltrating
encephalitogenic T cells) and a peripheral role
(mobilization in bone marrow and recruit-
ment of peripheral myeloid cells into the
CNS).9–11 However, in the EAE model, anti-
GM-CSF monoclonal antibodies ameliorate
the disease despite clear delineation of a central
vs a peripheral action of GM-CSF in EAE.
Positive results regarding tolerability and
efficacy in patients with rheumatoid arthritis14
indicate the potential of MOR103 in the treat-
ment of autoimmune diseases. We report re-
sults of a phase 1b trial of MOR103 in
patients with MS.
METHODS Patient selection. Patients were aged 18–60
years with a neurologist-confirmed diagnosis of relapsing-
remitting MS (RRMS) or secondary progressive MS (SPMS)
according to the 2005 revised McDonald diagnostic criteria.
They were also required to have a body mass index of 19.0–
35.0 kg/m2 and to agree to use effective contraceptive methods
and not to donate blood, sperm, or oocytes during and for $3
months after trial discontinuation. At screening, patients had to
be ambulatory, have an Expanded Disability Status Scale (EDSS)
score of $2.0 to #6.5, and have #10 gadolinium (Gd)-
enhancing brain lesions on T1-weighted MRI. In addition,
patients had to fulfill one of the following inclusion criteria:
$1 documented exacerbation within 1 year, 2 documented
exacerbations in the past 3 years, or a new T1 Gd-enhancing
brain lesion or T2 brain lesion within the past year.
Patients were excluded if they had primary progressive MS or if
they had not stabilized from an exacerbation occurring .30 days
prior to trial enrollment. They were also excluded if they had
received systemic glucocorticoids or adrenocorticotropic hormone
within 1 month; any interferon (IFN) b within 2 months; glatir-
amer acetate, plasmapheresis, or IV gamma globulin (IVIg) within 3
months; mycophenolate mofetil within 6 months; or azathioprine,
cyclosporine, or methotrexate within 12 months. Additional exclu-
sion criteria were previous treatment with B cell– or T cell–depleting
therapies, cytotoxic agents, any immunosuppressive/immunomodu-
lating agents (other than those listed above), total lymphoid irradi-
ation, stem cell therapy, or bone marrow transplantation.
Also excluded were patients with any medical condition or
uncontrolled disease state other than MS requiring or likely to
require systemic treatment with corticosteroids or other immuno-
modulators and those with a history of infection, tuberculosis,
hepatitis B or C, myocardial infarction, Class III or IV heart dis-
ease, hepatic or renal dysfunction, severe pulmonary disease, psy-
chiatric disorders, alcohol or drug abuse, or malignancy. Patients
who had received a live vaccine in the previous 6 months, who
had current or past clinically significant laboratory findings, or
who were pregnant or lactating were also excluded from the trial.
Study design. This was a multicenter, prospective, randomized,
double-blind, placebo-controlled, ascending dose-escalation phase
1b trial evaluating 3 dose levels of MOR103 (MorphoSys AG,
Martinsried/Planegg, Germany) for the treatment of RRMS and
SPMS. The primary objective was to determine the safety and
tolerability of MOR103 (level of evidence Class I); secondary
objectives included the multiple-dose pharmacokinetics (PK) and
potential immunogenicity of MOR103. Exploratory analyses
assessed changes from baseline in cytokine levels and in T cell
and monocyte subtypes.
An independent data monitoring committee (DMC) blinded
to treatment group reviewed interim safety data from all patients
in the 0.5 mg/kg and 1.0 mg/kg cohorts after the sixth dose of
study drug. DMC approval was required before proceeding to
the next higher dose level. A second safety review was performed
when all patients had completed their week 10 visit.
Patient eligibility was determined at screening and confirmed
at baseline before the first dose. Eligible individuals were random-
ized to receive IV MOR103 0.5, 1.0, or 2.0 mg/kg or placebo.
Randomization was in a 4:1 ratio (active treatment:placebo) in
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each of the 3 active dose groups, according to an interactive Web
response system randomization schedule. Each cohort was
planned to include 10 patients. Investigators and patients were
blinded to the randomization schedule and study drug. To avoid
unblinding of study treatments (MOR103 doses and matching
placebos), all relevant parts of the infusion set up had an opaque
protective cover of foil, paper, or plastic. Study drug was admin-
istered over 1 hour every 2 weeks for 10 weeks (6 doses), and pa-
tients were followed up for a further 10 weeks. Study drug was
discontinued due to adverse events (AEs) related to allergic-type
reactions or at the discretion of the investigator.
Patients were assessed at screening (days 235 to 210), at
baseline (day 1, first treatment day), on treatment days (days 15,
29, 43, 57, and 71), and during follow-up (days 85, 99, 113, and
141). In addition to inclusion/exclusion criteria evaluations, the
following assessments were performed at screening: demographic
characteristics, medical history, current/prior medications, phys-
ical examinations, vital signs, hematology, serum biochemistry,
whole blood flow cytometry, urinalysis, and EKGs.
Live vaccines, plasmapheresis, oral and parenteral glucocorti-
costeroids, glatiramer acetate, IVIg, immunosuppressive/immu-
nomodulating agents, and cytotoxic agents were prohibited
during the trial. Oral (high-dose) or parenteral corticosteroid
medication for exacerbations was permitted.
Standard protocol approvals, registrations, and patient
consents. This trial (registration number NCT01517282) was
conducted from January 2012 to February 2014 at 5 centers in
Germany, Poland, and the United Kingdom in accordance with
the Declaration of Helsinki, Seoul 2008, the International Con-
gress on Harmonization Good Clinical Practice Guidelines,
Directive 2001/20/EC, and the appropriate regulatory policies
and was approved by the independent ethics committee of each
investigator site. Individuals gave written informed consent for
participation and could voluntarily withdraw or be withdrawn
for any reason at the investigator’s discretion.
Safety and tolerability assessments. The primary endpoint
was the evaluation of the safety and tolerability of MOR103. On
treatment days and during follow-up, AEs (Medical Dictionary for
Regulatory Activities version 16.1) and concomitant medications
(World Health Organization Drug Dictionary September 1,
2011) were reported and data were collected from physical
examinations, vital signs, serum biochemistry, hematology,
pregnancy tests, and EDSS. MS exacerbation was defined as acute
worsening of one or more MS symptoms (e.g., numbness, loss of
muscle function, tremor, and gait or balance problems) or the
appearance of new symptoms lasting $24 hours and occurring
$1 month from the conclusion of a previous exacerbation.
Samples for laboratory analyses were collected before dosing, and
analyses were performed either at the site (urinalysis) or at a central
laboratory (INTERLAB GmbH, Munich, Germany). At intervals
throughout the trial, coagulation parameters, whole blood flow
cytometry (T cells [CD45RA, CD45RO, CD3, CD4] and
monocyte subtypes [CD14, CD16]), urinalysis, EKGs, and MRI
were evaluated. MRI was performed monthly to assess the number
of T1 Gd-enhancing and T2 brain lesions and the volume of T1-
hypointense and T2 lesions. MRI data were collected and analyzed
at a centralized MRI institution (Medical Image Analysis Center,
University Hospital Basel, Switzerland).
At baseline and at fixed intervals throughout the trial, serum
surfactant protein D (SSP-D) levels were measured and
pulmonary function tests (PFTs), including forced expiratory vol-
ume in the first second, vital capacity, forced vital capacity, and
diffusing capacity of the lung for carbon monoxide (DLCO),
were performed.
Serum levels of cytokines, including tumor necrosis factor a,
interleukin (IL)-1b, IL-6, IL-8, IL-10, IL-12, IL-17, IL-23,
IFN-g, and GM-CSF, were measured and analyzed at a central
laboratory (INTERLAB). Serum samples for anti-MOR103 anti-
bodies were collected at baseline and at weeks 14, 16, and 20 and
analyzed at a central bioanalytical laboratory (Eurofins Medinet
BV, Breda, the Netherlands) for serum IgG, IgA, and IgM iso-
types (INTERLAB).
Pharmacokinetic assessments. Serum MOR103 levels were
measured at baseline and week 10 before dosing and at 1 hour 6
5 minutes (i.e., end of infusion), 2 hours 6 5 minutes, and 4
hours6 5 minutes after the start of infusion; at weeks 2 through 8
before dosing and at 1 hour6 5 minutes after the start of infusion,
and at weeks 12, 14, 16, and 20. Serum samples were analyzed at a
central bioanalytical laboratory (Eurofins Medinet BV) using 2
different validated ligand binding assays detecting either free (bio-
active) drug levels or levels of MOR103 bound to GM-CSF.
Statistical analysis. Data were analyzed by descriptive statistics
using SAS for Windows, release 9.3 by INC Research and sum-
marized by dose level. Two analysis populations were defined: the
safety population (all randomized patients who received $1 dose
of study drug and had$1 safety assessment after dosing) and the
PK population (all randomized patients who received study drug
and had$1 PK sample after dosing). PK parameters were derived
by noncompartmental analysis as data allowed. Dose proportion-
ality was analyzed using the method proposed by Hummel et al.15
Missing data were not imputed but treated as missing with the
following exceptions: if AE severity or relationship to study drug
was missing, the event was considered to be severe and/or related
to study drug (worst case principle); if the AE onset date was miss-
ing or incomplete, it was assumed to be a treatment-emergent AE
(TEAE; unless otherwise indicated); and if the drug start and/or
stop date was missing or incomplete, it was assumed that the drug
was concomitant to study treatment (unless otherwise indicated).
Each patient was randomly assigned to MOR103 or placebo
in a ratio of 4:1 to minimize the number of patients with MS
receiving placebo while providing sufficient data to assess safety
and ascertain adequate MOR103 exposure. No statistical as-
sumptions of power, error rate, or safety margins were used to
determine sample size. Ten patients per cohort is a typical sample
size for phase 1b studies.
Classification of evidence. This study was designed to answer
the following primary research question: is IV MOR103 0.5–2.0
mg/kg administered at 2-week intervals of acceptable safety and
tolerance to patients with RRMS or SPMS? This phase 1b study
provides Class I evidence that MOR103 has acceptable tolerability
in patients with MS. The majority of TEAEs were of mild or
moderate intensity, and TEAEs and those events considered to
be related to study drug occurred at a comparable or lower rate
in the MOR103 groups compared with the placebo group.
RESULTS Patient disposition. Of the 57 patients
screened, 32 were randomized, 31 received $1 dose
of study drug, and 27 (84.4%) completed the trial
(figure 1). One randomized patient did not receive
treatment and was excluded from the analyses. All 31
treated patients were included in the safety popula-
tion and all 25 patients on active treatment were
included in the PK population.
All patients received all 6 doses of study drug
except for 1 patient in the MOR103 1.0 mg/kg group
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and 2 in the 2.0 mg/kg group (due to exacerbation or
withdrawal). The duration and volume of each infu-
sion was generally within the predefined ranges (dura-
tion 58–62 minutes; volume 490–510 mL).
Baseline demographic and clinical characteristics
of patients were generally comparable among the
treatment groups (table 1). However, the MS types
were not distributed equally over the treatment
groups: although the majority of patients in all groups
were diagnosed with RRMS, the placebo group con-
sisted of only patients with RRMS and the MOR103
2.0 mg/kg group had 3 patients with SPMS. In addi-
tion, the mean time since diagnosis was longer in the
higher MOR103 dose groups than in the MOR103
0.5 mg/kg and placebo groups. Also, the number of
exacerbations, patients with Gd-enhancing lesions,
median T1-hypointense lesion volume, and median
T2 lesion volume (data not shown) were unequally
distributed between the cohorts.
Safety and tolerability. A total of 184 TEAEs were re-
ported in 31 (96.8%) patients (table 2), with no over-
all indication of increased TEAE frequencies in the
MOR103 groups compared with placebo. The most
common TEAEs in all groups were nasopharyngitis,
headache, and MS exacerbation. No cases of infusion-
related reaction were reported.
Eleven MS exacerbation events occurred in 9 pa-
tients. MS exacerbation occurred in 3 (50.0%), 5
(62.5%), 1 (12.5%), and 0 (0%) patients in the placebo,
MOR103 0.5, 1.0, and 2.0 mg/kg groups, respectively.
Events occurred in both the treatment and follow-up
periods in the placebo and MOR103 0.5 mg/kg groups
and during follow-up in theMOR 1.0 mg/kg group. All
events either resolved/recovered or were resolving/recov-
ering at the end of the follow-up period; recovery with
sequelae was reported for 3 exacerbations. Four exacer-
bation events required medication, including 2 serious
events requiring hospitalization (1 patient in the placebo
group and 1 patient in the MOR103 1.0 mg/kg group).
The latter were of moderate intensity, were considered
not related to treatment, and resolved after medication.
One exacerbation event was considered to be “probably”
related to treatment (placebo) by the investigator; the
remainder were considered to be possibly (4 events),
unlikely (3 events), or not (3 events) treatment-related
by investigators.
TEAEs by system organ class generally occurred
with similar frequencies in the 4 treatment groups.
The most common were infections, occurring in 4
(66.7%), 5 (62.5%), 6 (75.0%), and 5 (55.6%) pa-
tients in the placebo, MOR103 0.5, 1.0, and 2.0
mg/kg groups, respectively. Nervous system disorders
occurred in 5 (83.3%), 6 (75.0%), 4 (50.0%), and
3 (33.3%) patients in the placebo, MOR103 0.5,
1.0, and 2.0 mg/kg groups, respectively.
A total of 71 TEAEs considered to be possibly,
probably, or definitely related to treatment were re-
ported in 18 (58.1%) patients (table 3). MS exacer-
bation and headache occurred in the placebo and
MOR103 0.5 mg/kg groups only, whereas a mild
increase in C-reactive protein was reported for
1 patient in each of the higher MOR103 dose groups.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis
aPatients received 2 doses of study drug before trial withdrawal. bOne patient became pregnant during the trial and therefore did not receive treatment at
weeks 8 and 10 (received 4 doses of study drug).
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TEAEs were generally of mild or moderate
intensity. There were 2 severe TEAEs (urinary tract
infection, placebo group; decreased vibratory sense
in right lower limb, MOR103 2.0 mg/kg group);
both were considered unlikely to be related to
treatment. No additional serious TEAEs (aside
from the aforementioned MS exacerbations) were
reported. No TEAEs led to death or trial discontin-
uation. One woman became pregnant and discon-
tinued study drug after 4 doses but remained in
the trial for observational follow-up (pregnancy
terminated).
There were no clinically significant changes in
vital signs, EKG, PFTs (including DLCO), or hema-
tology, serum chemistry, or urine parameters during
treatment. While whole blood flow cytometry (T cells
[CD45RA, CD45RO, CD3, CD4] and monocyte
subtypes [CD14, CD16]) was monitored, no differ-
ences or trends were observed in any of the flow
cytometry parameters when comparing the active
treatment groups with placebo. EDSS remained gen-
erally stable, with small changes indicating worsening
(scores 10.5 to 11.0) usually associated with MS
exacerbation. No clinically important differences
between active treatment and placebo in these meas-
ures were observed.
A few T1 Gd-enhancing and/or new or enlarging
T2 lesions indicative of inflammation were observed
(table 4).
Given that GM-CSF and alveolar macrophages are
regulators of lung surfactant homeostasis and that
pulmonary alveolar proteinosis has been associated
with neutralizing anti-GM-CSF antibodies,16 we
measured SSP-D levels and performed PFTs (includ-
ing DLCO) to evaluate potential lung toxicity.
SSP-D levels showed some variability throughout
the trial, although no consistent increase was observed
for any cohort. There were no clinically relevant dif-
ferences in PFTs in the MOR103 groups or reports of
cough or dyspnea.
Peripheral blood cytokines, including GM-CSF,
were usually near or below the respective lower limits
of quantification and showed no notable or consistent
changes related to MOR103 infusions throughout
the trial. Serum samples did not test positive for
anti-MOR103 antibodies, and there was no evidence
of any treatment difference in serum IgG, IgA, and
IgM isotype concentrations.
Pharmacokinetics. Observed MOR103 serum concen-
trations over time are presented in figure 2. PK data
analysis was based on free MOR103 serum levels. On
day 1, median time of the apparent maximum con-
centration was 1.0–2.0 hours after the start of the
infusion. The geometric mean apparent maximum
concentration and apparent area under the serum
concentration vs time curve (AUCtau) were dose pro-
portional in the range of 0.5–2.0 mg/kg. Following











Age, y, mean (SD) 43.5 (15.0) 47.8 (10.6) 48.6 (5.0) 48.3 (11.5)
BMI, kg/m2, mean (SD) 26.8 (6.1) 26.9 (3.7) 27.6 (4.4) 26.2 (4.2)
Female, n (%) 3 (50.0) 4 (50.0) 6 (75) 7 (77.8)
Ethnicity, n (%)
White 5 (83.3) 7 (87.5) 8 (100) 9 (100)
Black/American African 0 (0) 1 (12.5) 0 (0) 0 (0)
Asian 1 (16.7) 0 (0) 0 (0) 0 (0)
Time since MS diagnosis, ya 5.5 (7.7) 5.6 (8.7) 13.1 (7.4) 10.7 (9.0)
Diagnosis, n (%)b
RRMS 6 (100) 7 (87.5) 6 (75.0) 6 (66.7)
SPMS 0 (0.0) 1 (12.5) 1 (12.5) 3 (33.3)
Unknown 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0)
EDSS score, mean (SD) 3.8 (1.5) 4.0 (1.7) 3.9 (1.8) 4.3 (1.8)
Abbreviations: BMI 5 body mass index; EDSS 5 Expanded Disability Status Scale; MS 5 multiple sclerosis; RRMS 5
relapsing-remitting MS; SPMS 5 secondary progressive MS.
a The time since MS diagnosis was calculated as the integer value of (date of informed consent - date of first diagnosis)/
365.25.
b For 1 patient, the MS diagnosis is unknown and confirmed by investigator as “unclear if RRMS or SPMS, but primary
progressive MS is definitely excluded.”
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noncompartmental data analysis, the mean apparent
terminal half-life was approximately 17 days across all
dose groups, and mean AUCtau accumulation as a
result of multiple dosing was approximately 20%–
32%. MOR103/GM-CSF complexes (bound drug
levels) in serum were close to the limit of
quantification at 20 pM or not detectable.
DISCUSSION This randomized, double-blind,
placebo-controlled, sequential ascending-dose trial
was designed to evaluate the effects of neutralizing
GM-CSF using MOR103 in patients with MS. The
primary objective was to determine the safety and
tolerability of MOR103 in patients with RRMS or
SPMS. MOR103 administered at 3 different doses
at 2-week intervals was well-tolerated in patients
with MS.
The majority of TEAEs were of mild or moderate
intensity, and only 2 events were considered to be
serious. TEAEs and those events considered to be
related to study drug occurred at a comparable or
lower rate in the MOR103 groups compared with
the placebo group. Of note, no increase in the inci-
dences of nasopharyngitis, MS exacerbation, and
headache (the most frequently reported AEs) were
observed with higher MOR103 doses. The incidences
of treatment-related nasopharyngitis, MS exacerba-
tion, and headache were similar between the













Patients with ‡1 treatment-emergent
AE, n (%)
6 (100) 8 (100) 8 (100) 8 (88.9) 24 (96.0)
No. of treatment-emergent AEs
Total 44 83 31 26 140
Events/patient 7.3 10.4 3.9 2.9 5.6
Patients with ‡1 treatment-emergent
AE, n (%)
Nasopharyngitis 4 (66.7) 4 (50.0) 3 (37.5) 1 (11.1) 8 (32.0)
Multiple sclerosis exacerbationa 3 (50.0) 5 (62.5)b 1 (12.5) 0 (0.0) 6 (24.0)
Headache 2 (33.3) 1 (12.5) 3 (37.5) 1 (11.1) 5 (20.0)
Sensory disturbance 0 (0.0) 3 (37.5) 0 (0.0) 1 (11.1) 4 (16.0)
Back pain 0 (0.0) 3 (37.5) 0 (0.0) 0 (0.0) 3 (12.0)
Fatigue 2 (33.3) 2 (25.0) 0 (0.0) 1 (11.1) 3 (12.0)
Extremity pain 0 (0.0) 1 (12.5) 1 (12.5) 1 (11.1) 3 (12.0)
Reduced visual acuity 0 (0.0) 3 (37.5) 0 (0.0) 0 (0.0) 3 (12.0)
Arthralgia 0 (0.0) 1 (12.5) 1 (12.5) 0 (0.0) 2 (8.0)
Increased C-reactive protein 0 (0.0) 0 (0.0) 1 (12.5) 1 (11.1) 2 (8.0)
Cough 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0) 2 (8.0)
Diarrhea 0 (0.0) 0 (0.0) 1 (12.5) 1 (11.1) 2 (8.0)
Eye pain 0 (0.0) 1 (12.5) 1 (12.5) 0 (0.0) 2 (8.0)
Gastroenteritis 0 (0.0) 0 (0.0) 0 (0.0) 2 (22.2) 2 (8.0)
Rhinitis 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0) 2 (8.0)
Urinary tract infection 1 (16.7) 0 (0.0) 1 (12.5) 1 (11.1) 2 (8.0)
Increased white blood cell count 0 (0.0) 1 (12.5) 1 (12.5) 0 (0.0) 2 (8.0)
Decreased vibratory sense 1 (16.7) 0 (0.0) 0 (0.0) 1 (11.1) 1 (4.0)
Muscle twitching 1 (16.7) 1 (12.5) 0 (0.0) 0 (0.0) 1 (4.0)
Paresthesia 2 (33.3) 0 (0.0) 0 (0.0) 1 (11.1) 1 (4.0)
Pollakiuria 1 (16.7) 1 (12.5) 0 (0.0) 0 (0.0) 1 (4.0)
Blurred vision 1 (16.7) 1 (12.5) 0 (0.0) 0 (0.0) 1 (4.0)
aWorsening of existing multiple sclerosis.
b Includes 1 patient who was reported under the preferred term “gait disturbance.”
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MOR103 0.5 mg/kg group and the placebo group.
Nasopharyngitis was also reported to be the most
common treatment-related AE in patients with rheu-
matoid arthritis treated with MOR103.14
Exacerbations occurred in both the treatment and
follow-up periods in patients receiving MOR103 0.5
and 1.0 mg/kg. Whether this indicates a potential for
a rebound effect at these doses remains to be
Table 3 Incidence of treatment-emergent adverse events (AEs) considered to be possibly, probably, and
definitely related to study drug in patients in any treatment group













Patients with ‡1 treatment-emergent AE
related to study drug,a n (%)
5 (83.3) 6 (75.0) 4 (50.0) 3 (33.3) 13 (52.0)
No. of treatment-emergent AEs related to
study druga
Total 21 35 8 7 50
Events/patient 3.5 4.4 1.0 0.8 2.0
Patients with ‡1 treatment-emergent AE
related to study drug,a n (%)
Nasopharyngitis 3 (50.0) 2 (25.0) 1 (12.5) 0 (0.0) 3 (12.0)
Multiple sclerosis exacerbationb 2 (33.3) 2 (25.0) 0 (0.0) 0 (0.0) 2 (8.0)
Fatigue 1 (16.7) 1 (12.5) 0 (0.0) 1 (11.1) 2 (8.0)
Increased C-reactive protein 0 (0.0) 0 (0.0) 1 (12.5) 1 (11.1) 2 (8.0)
Extremity pain 0 (0.0) 1 (12.5) 1 (12.5) 0 (0.0) 2 (8.0)
Headache 2 (33.3) 1 (12.5) 0 (0.0) 0 (0.0) 1 (4.0)
Paresthesia 1 (16.7) 0 (0.0) 0 (0.0) 1 (11.1) 1 (4.0)
a Includes AEs considered to be possibly, probably, and definitely related to study drug.
bWorsening of existing multiple sclerosis.




























Screening 6 4/3 8 6/3 8 3/3 9 1/1a 25 10/7
Week 4 6 4/2 8 8/4b 6 1/1 8 1/1 22 10/6
Week 8 6 3/2 8 3/2 6 2/2 7 1/1 21 6/5
Week 12 4 0 8 11/3b 6 3/1c 7 1/1 21 15/5
Week 16 5 3/2 8 8/2b 6 6/1c 7 1/1 21 15/4
New or enlarging
T2 lesions
Week 8 6 9/3 8 23/7d 6 3/2 7 2/1 21 28/10
Week 12 4 1/1 8 9/2d 6 3/1e 7 0 21 12/3
Week 16 5 5/3 8 16/2d 6 9/2e 7 0 21 25/4
aThis patient showed 1 new lesion at each time point.
bMajority of lesions (4 lesions at week 4, 8 at week 12, and 7 at week 16) were in 1 patient.
c The same patient.
dMajority of lesions were in 1 patient.
eMajority of lesions were in 1 patient.
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determined. MRI examinations did not demonstrate
any evidence of increased lesional activity or oppor-
tunistic CNS infections in patients treated with
MOR103.
The assumption that MOR103 has a low immu-
nogenic potential in patients with MS was con-
firmed by this trial, as no anti-MOR103–positive
samples were detected throughout the complete
trial.
The PK profile demonstrating dose linearity
between MOR103 0.5 and 2 mg/kg and a terminal
elimination half-life of approximately 17 days is com-
parable with previously reported results for other
human IgG1 antibodies targeting proinflammatory
cytokines.17,18
The limitations of this trial mostly apply to phase
1/2 clinical trials in general, including small sample
size and limited duration. While not unexpected,
the slight bias in the baseline characteristics needs
to be acknowledged.
This trial demonstrates that MOR103 is well-
tolerated with no unexpected safety concerns in the
treatment of MS. These findings are consistent with
prior safety data reported for patients with rheuma-
toid arthritis.14 Therefore, the use of GM-CSF anti-
bodies may provide a novel approach to addressing
the unmet need for MS therapies.
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